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Natriuretic peptide receptors regulate
cytoprotective effects in a human ex vivo
3D/bioreactor model
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Amie J Moyes5, Adrian J Hobbs5 and Tina T Chowdhury1*
Abstract
Introduction: The present study examined the effect of C-type natriuretic peptide (CNP) and biomechanical signals
on anabolic and catabolic activities in chondrocyte/agarose constructs.
Methods: Natriuretic peptide (Npr) 2 and 3 expression were compared in non-diseased (grade 0/1) and diseased
(grade IV) human cartilage by immunofluoresence microscopy and western blotting. In separate experiments,
constructs were cultured under free-swelling conditions or subjected to dynamic compression with CNP,
interleukin-1b (IL-1b), the Npr2 antagonist P19 or the Npr3 agonist cANF4-23. Nitric oxide (NO) production,
prostaglandin E2 (PGE2) release, glycosaminoglycan (GAG) synthesis and CNP concentration were quantified using
biochemical assays. Gene expression of Npr2, Npr3, CNP, aggrecan and collagen type II were assessed by real-time
qPCR. Two-way ANOVA and a post hoc Bonferroni-corrected t-test were used to analyse the data.
Results: The present study demonstrates increased expression of natriuretic peptide receptors in diseased or older
cartilage (age 70) when compared to non-diseased tissue (age 60) which showed minimal expression. There was
strong parallelism in the actions of CNP on cGMP induction resulting in enhanced GAG synthesis and reduction of
NO and PGE2 release induced by IL-1b. Inhibition of Npr2 with P19 maintained catabolic activities whilst specific
agonism of Npr3 with cANF4-23 had the opposite effect and reduced NO and PGE2 release. Co-stimulation with
CNP and dynamic compression enhanced anabolic activities and inhibited catabolic effects induced by IL-1b. The
presence of CNP and the Npr2 antagonist abolished the anabolic response to mechanical loading and prevented
loading-induced inhibition of NO and PGE2 release. In contrast, the presence of the Npr3 agonist had the opposite
effect and increased GAG synthesis and cGMP levels in response to mechanical loading and reduced NO and PGE2
release comparable to control samples. In addition, CNP concentration and natriuretic peptide receptor expression
were increased with dynamic compression.
Conclusions: Mechanical loading mediates endogenous CNP release leading to increased natriuretic peptide
signalling. The loading-induced CNP/Npr2/cGMP signalling route mediates anabolic events and prevents catabolic
activities induced by IL-1b. The CNP pathway therefore represents a potentially chondroprotective intervention for
patients with OA, particularly when combined with physiotherapeutic approaches to stimulate biomechanical
signals.
* Correspondence: t.t.chowdhury@qmul.ac.uk
1School of Engineering and Materials Science, Queen Mary University of
London, Mile End Road, London E1 4NS, UK
Full list of author information is available at the end of the article
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Introduction
There is an urgent demand for long-term solutions to
improve osteoarthritis (OA) treatment in the ageing
population. There are drugs that control the pain but
none that stop the progression of the disease in a safe
and efficient way. More effective intervention, augmen-
ted by early diagnosis and integrated biophysical thera-
pies are therefore needed. Unfortunately, progress has
been slow due to the wide variety of experimental mod-
els that examine the effect of mechanical stimuli and
chondroprotective agents on signal transduction path-
ways. Accordingly, our understanding of the early
mechanopathophysiology is poor, particularly the way in
which mechanical stimuli influence cell function and
regulate matrix synthesis. This makes it difficult to iden-
tify reliable targets and design new therapies for OA
treatment.
Growing evidence suggests that stimulation of the
C-type natriuretic peptide (CNP) signalling pathway may
contribute to anabolic events and potentially provide a
new therapeutic application for conditions with loss of
cartilage matrix. For example, treatment with CNP has
been reported to increase both collagen and proteoglycan
synthesis and to enhance cell proliferation in chondrocytes
cultured in monolayer or pellet culture [1,2]. In an ex vivo
human chondrocyte three-dimensional (3D)/bioreactor
model, we showed increased cell proliferation and proteo-
glycan synthesis, and suppression of catabolic activities in
response to CNP [3]. Indeed, in our previous study, exo-
genous CNP was found to be protective and mediates
enhanced cell proliferation and extracellular matrix synth-
esis via 3, 5-cyclic guanosine monophosphate (cGMP)-
dependent protein kinase II (PKGII). Furthermore, the
protective effects of CNP were enhanced with stimulation
by mechanical loading in human chondrocyte/agarose
constructs cultured with IL-1b. However, the interplay of
CNP and biomechanical signals in IL-1b-treated chondro-
cytes has not been examined in detail. In a previous study,
the natriuretic peptide receptor (Npr)2guanylyl cyclase B
and -cGMP (Npr2/cGMP) pathway was shown to mediate
increased cell proliferation in rat chondrocytes treated
with CNP [4]. In this model, upregulation of the
Npr2cGMP system by CNP is essential for cartilage devel-
opment and involves PKGII mechanisms in late prolifera-
tive and pre-hypertrophic zones of growth-plate cartilage
[4-9]. Furthermore, disruption of the genes encoding CNP
and PKGII results in impaired growth of endochondral
bones and leads to severe dwarfism and skeletal defects
[5-7]. Conversely, overexpression of CNP results in skele-
tal overgrowth and rescued dwarfism in a murine model
of human achondroplasia [9]. Taken together, the in vitro
and genetic studies highlight the importance of CNP sig-
nalling in cartilage and bone remodelling, and offers the
potential of CNP in the treatment of OA and skeletal
diseases.
The molecular mechanisms underpinning CNP regula-
tion of cartilage remodelling remain elusive. CNP binding
to Npr2 leads to increased cGMP levels, which modulates
the downstream activities of PKGs, cGMP-regulated ion
channels (CGi) and cGMP-regulated phosphodiesterase
(PDE) subtypes [6,10,11]. In contrast, Npr3 does not pos-
sess a guanylyl cyclase domain and until recently, was
thought to act as a decoyclearance receptor, thereby reg-
ulating CNP signalling [12]. It is now apparent Npr3
mediates several signalling effects in rat osteoblasts and
inhibits adenylate cyclase or stimulates the G1 protein-
phospholipase C pathway, which acts as a positive regula-
tor of bone [13]. Furthermore, CNP has been shown to
mediate a vasoprotective profile via Npr3-dependent
extracellular signal-regulated kinase (ERK) 1/2 phosphor-
ylation, resulting in augmented endothelial cell prolifera-
tion and inhibition of vascular smooth muscle growth
[14]. Characterization of the Npr2 and Npr3 signalling
cascade in cartilage has not been investigated previously
and a greater understanding of the mechanism underpin-
ning these pathways is needed. We hypothesise that the
Npr2 and Npr3 pathways have overlapping protective
roles in maintaining cartilage homeostasis and may slow
pathogenesis and restore tissue damage in vivo. In addi-
tion, mechanical loading could interfere with the Npr
pathways and augment an anabolic response. The present
study therefore examined the relationship between
mechanical loading and CNP signalling in detail and
determined whether the Npr cascade in combination
with mechanical signals demonstrates a chondroprotec-
tive profile in vitro.
Materials and methods
Chondrocyte isolation and culture in agarose constructs
Human cartilage was obtained from twenty patients (age
55 to 75 years), with ethical approval (East London and
The City Research Ethics Committee) and informed
patient consent, undergoing total knee arthroplasty at
the Royal London Hospital, Barts Health NHS Trust,
London, UK. Cartilage was removed from the femoral
condyles and tibial plateaux. The morphology of the car-
tilage specimens was graded for gross degenerative
changes according to the International Cartilage Repair
Society (ICRS) classification, and tissues that represent
non-diseased (grade 0 or 1) and early (grade 2) OA
were used for experiments. Each experimental condition
was repeated with chondrocytes from four to five differ-
ent donors. Cartilage tissue was diced and incubated on
rollers for 1 hour at 37°C in DMEM supplemented with
10% (vol/vol) (FCS) + 2 μM L-glutamine, 5 μg/ml peni-
cillin, 5 μg/ml streptomycin, 20 mM Hepes buffer, and
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0.05 mg/ml L-ascorbic acid + 700 unit/ml pronase, and
incubated for a further 16 hours at 37°C in DMEM +
10% FCS, supplemented with 100 units/ml collagenase
type XI (Sigma-Aldrich, Poole, UK). The cell suspension
was washed and viable chondrocytes counted using a
hemocytometer and trypan blue. Cells were finally
resuspended in medium at a cell concentration of 8 ×
106 cells/ml by using a well-established protocol [15,16].
In brief, the cell suspension was added to an equal
volume of molten 6% (wt/vol) agarose type VII in Earle
Balanced Salt Solutions (EBSS) to yield a final cell con-
centration of 4 × 106 cells/ml in 3% (wt/vol) agarose
(Sigma-Aldrich). The chondrocyte/agarose suspension
was transferred into a sterile stainless steel mould, con-
taining holes 5 mm in diameter and 5 mm in height
and allowed to gel at 4°C for 20 minutes. Constructs
were cultured in DMEM + 10% FCS at 37°C in 5% CO2
for 24 hours (all from Cambrex Bioscience, Wokingham,
UK).
Effect of pharmacological agents that influence
natriuretic peptide signalling in chondrocyte/agarose
constructs
The effect of pharmacological agents that influence the
natriuretic peptide and cGMP pathway were examined in
constructs cultured under free-swelling conditions. This
approach allowed us to determine their effects on protein
synthesis in the absence of mechanical loading. Constructs
were cultured in 1 ml of defined media supplemented with
100 nM CNP in the presence and absence of 10 ng/ml
IL-1b and/or 5 μM specific sGC antagonist (1H-(1,2,4)oxa-
diazolo-(4, 3-a)quinoxalin-1-one) (ODQ) and/or 1 μM
selective Npr3 agonist cANF4-23 (C-Atrial Natriuretic Fac-
tor) (Bachem AG, Bubendorf, Switzerland) and/or 0.5 μM
selective Npr2 antagonist cyclic gly-24-ser (P19, Gentaur
Molecular Products, Whetstone, UK) for 48 hours [17,18].
At the end of the culture period, the constructs and corre-
sponding media were immediately stored at -20°C before
biochemical analysis.
Application of dynamic compression
In separate experiments, a fully characterized bioreactor
compression system (Bose ElectroForce, GillinghamUK)
was used to determine the effect of dynamic compres-
sion and chemical agents, which influence the natriure-
tic peptide signalling pathway, on cell metabolism and
gene expression in CNP andor IL-1b-treated chondro-
cyte/agarose constructs. The bioreactor has been exten-
sively described previously [15,16,19]. To review briefly,
equilibrated constructs were transferred into individual
wells of a 24-well culture plate (Costar, High Wycombe,
UK) and mounted within the bioreactor. Media supple-
mented with 0 or 10 ng/ml IL-1b in the presence and
absence of 100 nM CNP and/or 0.5 μM P19 and/or
1 μM cANF4-23 was introduced into each well. Strained
constructs were subjected to dynamic compression ran-
ging from 0 to 15% strain in a sinusoidal waveform at a
frequency of 1 Hz. The compression regimen was
applied in an intermittent manner, with a profile of
1.5-hour compression followed by a 4.5-hour unstrained
period for both 6- and 48-hour culture periods, as pre-
viously described [3]. This resulted in duty cycles
equivalent to 5,400 and 43,200 respectively. Control
constructs were maintained in an unstrained state
within the bioreactor system and cultured for the same
time period. At the end of the culture period, the con-
structs and corresponding media were immediately
stored at -70°C before analysis.
RNA isolation, cDNA synthesis, and real-time
quantitative PCR
RNA was isolated from chondrocytes cultured in agar-
ose by using protocols described in the QIAquick Spin
gel extraction and RNeasy kits, as previously described
(Qiagen, Crawley, West Sussex, UK) [20,21]. By follow-
ing the manufacturer’s instructions, Ambion’s DNA-free
DNase treatment and removal reagents were used to
eliminate any contaminating DNA from the RNA sam-
ple (Ambion Applied Biosystems, Warrington, UK).
RNA was quantified on the Nanodrop ND-1000 spectro-
photometer (LabTech, Uckfield, East Sussex, UK), and
reverse transcription was performed using the manufac-
turer’s protocols from the Enhanced Avian RT First
Strand cDNA synthesis kit, oligo(dT)23 primer, and a
total of 200 ng of RNA (Sigma Genosys, Cambridge,
UK). Real-time quantitative (q)PCR assays coupled with
locked nucleic acid (LNA) probes were performed in
25-μl reaction mixtures containing 1 μl cDNA, 12.5 μl
JumpStart Taq PCR Master Mix, primer pairs, probes
detailed in Table 1 and nuclease-free PCR-grade water
to 25 μl (Sigma Genosys). Each sample was run in
duplicate on the 96-well thermal system of the
Mx3000P qPCR instrument (Stratagene, Amsterdam,
The Netherlands). Thermocycling conditions comprised
an initial polymerase activation step at 95°C for 3 min-
utes, followed by denaturation of 35 cycles at 95°C for
30 seconds, annealing at 55°C for 1 minute, and exten-
sion at 72°C for 1 minute. PCR efficiencies for optimal
primer pair and probe concentrations were derived from
standard curves (n = 3) by preparing a 10-fold serial
dilution of cDNA from a sample that represented the
untreated control at time-zero conditions. The real-time
PCR efficiencies (E) of amplification for each target
were defined according to the relation, E = 10(-1/slope).
The R2 value of the standard curve exceeded 0.9998 and
revealed efficiency values ranging from 1.94 to 2.03.
Fluorescence data were collected during the annealing
stage of amplification, and data were analyzed on the
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MxPro qPCR software (version 3, Stratagene). Baselines
and thresholds were automatically set by the RG-3000
qPCR software and used after manual inspection. The
cycle threshold (Ct) value for each duplicate reaction
was expressed as the mean value, and the results were
exported into Microsoft Excel for further analysis. The
data obtained by PCR assay for glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) were validated as a
reference gene by displaying the Ct values as box-and-
whisker plots, and the distribution examined under the
treatment conditions (data not shown). The Ct values
for GAPDH remained stable, with no changes detected
under all culture conditions, suggesting its suitability as
a reference gene. Relative quantification of Npr2, Npr3,
CNP, aggrecan and collagen type II signals were estimated
by normalizing each target to the reference gene, GAPDH,
and to the calibrator sample (unstrained, untreated con-
trol) by a comparative Ct approach. For each sample, the
ratio of target ΔCt and reference ΔCt was calculated, as
previously described [20-22].
Biochemical analysis
The production of nitric oxide (NO) was determined in
media by converting nitrate to nitrite by using 1 unit/ml
nitrate reductase in 40 μM nicotinamide adenine dinu-
cleotide phosphate-oxidase (NAPDH), 500 μM glucose
6-phosphate, 160 unit/ml glucose 6-phosphate dehydro-
genase and 20 mM Tris-HCL for 15 minutes at 37°C.
Total nitrite was assayed spectrophotometrically at 540 nm
using the Griess reaction, as previously described [23].
PGE2 production was measured in the culture media using
a high-sensitivity enzyme immunoassay according to man-
ufacturer’s instructions (R & D systems, Abingdon UK).
GAG synthesis was measured in constructs digested over-
night at 37°C with 10 U/ml agarase followed by 1 hour at
60°C with 2.8 U/ml papain (both Sigma Chemical Co.,
Poole, UK) and analyzed with using the DMMB assay as
previously described [15]. Total DNA levels were assayed
by using the Hoescht dye 33258 in agarose/papain digests
[15]. Values for total DNA content remained stable
throughout the culture conditions with no significant
differences between any treatments. Intracellular and extra-
cellular cGMP was measured in cell lysates and superna-
tants by ELISA (R & D Systems), in the presence of the
pan-PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX,
Sigma-Aldrich). CNP concentration was determined by
concentrating the cell culture supernatants on C18 SEP-
columns according to the CNP-22 EIA assay kit instruc-
tions (Phoenix Pharmaceuticals, Mannheim, Germany).
The supernatants (700 ul) were acidified with an equal
volume of buffer A, centrifuged and loaded onto columns
and equilibrated with buffer A. Each sample was applied to
a separate column and allowed to flow through by gravity.
Columns were washed twice with 3 ml of buffer A and the
CNP eluted with 3 ml of buffer B. The eluate was then eva-
porated to dryness in a centrifugal speed vacuum and the
residue dissolved in 125 μl of EIA assay buffer. CNP con-
centrations were determined according to the manufac-
turer’s instructions.
Paraffin embedding, sectioning and detection of
natriuretic peptide receptors by immunofluorescence
microscopy
Non-diseased (grade 0 to 1) and diseased (grade IV) carti-
lage specimens from eleven donors (age range 58 to 84
years) were fixed, paraffin-embedded and serially sectioned
Table 1 Description of the LNA probe and primer sequences used to quantify gene expression
Gene Gene ID Sequences Product length
Npr2 4882 Probe: 5’-FAM-ATCGCTGGCTGCTTCTATG-BHQ1-3’
Sense: 5’-CCCTTCCCTGATGAACCT -3’
Antisense: 5’-CCCTGCATCTTTTCCACAA -3’
132
Npr3 4883 Probe: 5’-FAM-TTCTCTCCAAAGGTTCCCG-BHQ1-3’
Sense: 5’ TTTAAGAAAAACTAGTGACATTGGA-3’
Antisense: 5’- CCACCCTTCCTCTTTCCT-3’
146
CNP 4880 Probe: 5-’FAM-CGCCAATCTCAAGGGC-BHQ1-3’
Sense: 5’-TCAGAAGAAGGGCGACAA -3’
Antisense: 5’-TGGCTCCTTTGTATTTGCG -3’
158
GAPDH 2597 Probe: 5’-HEX-CAGTCAGCCGCATCTTCT-BHQ1-3’
Sense: 5’-TCTCTGCTCCTCCTGTTC-3’
Antisense: 5’-CGCCCAATACGACCAAAT-3’
160
Aggrecan 176 Probe: 5-’FAM-CCAACTCTTCAAGGTGA-BHQ1-3’
Sense: 5’-GACTGAAGTTCTTGGAGAA-3’
Antisense: 5’-CACGAAAACCCAGAGTAA-3’
109
Collagen type II 1280 Probe: 5’-FAM-TCTGTCTCCTTGCTTGCCA-BHQ1-3’
Sense: 5’-GGAGTCAAGGGTGATCGT-3’
Antisense: 5’-CTTGTGCACCAGCTTCTC-3’
200
Primers used in PCR experiments with locked nucleic acid (LNA) probes produced amplicons between 132 and 160 base pairs. Probes contain fluorescein (FAM)
or 6-carboxyhexafluorescein (HEX) as the 5’-reporter dye and Black Hole Quencher 1 (BHQ1) as the 3’-quencher. Nucleotides highlighted in bold denote the LNA
base.
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in a sagittal plane at 10-μm intervals. Tissue morphology
was assessed by H&E or Safranin-O fast green staining for
highly sulphated, negatively charged GAGs. Slides were
analysed on the Leica microscope and images captured
with a Hamamatsu digital camera and HiPic32 imaging
software. Slides were deparaffinized with xylene, rehy-
drated through a series of decreasing concentrations of
ethanol and washed with tris-buffered saline (TBS) for
5 minutes. Antigen retrieval was achieved with 0.02% HCL
at 37°C for 15 minutes, followed by 2.5 mg/mL pepsin in
0.02% HCL at 37°C for 45 minutes. After 3 × TBS washes
for 5 minutes, sections were blocked using avidin (10 min-
utes), biotin (10 minutes) and protein (20 minutes) block
(all reagents obtained from DAKO Ely, UK) and incubated
with primary antibodies for Npr2 (ab37620) and Npr3
(ab97389, AbCam, Cambridge, UK) overnight at 4°C.
Detection was performed by incubating sections with anti-
rabbit biotinylated secondary antibodies at a dilution of
1:100 in antibody diluent (all reagents from DAKO) for
1 hour, streptavidin-488 at 1:300 for 30 minutes, 4’,6-dia-
midino-2-phenylindole (DAPI) at 1 μg/mL for 10 minutes,
with washing 3 × 5 minutes in TBS after each incubation.
Sections were mounted with ProLong antifade (Invitrogen,
Paisley, UK), and captured with Image J software by confo-
cal microscopy using 20 × or 63 × objectives (Leica Confo-
cal Microsystem, Milton Keynes, UK). The number of cells
positive in the 488 nm channel was counted from a mini-
mum of 30 cells/slide, and the percentage of positively
stained cells calculated from the total number of DAPI-
positive cells. All images were processed with Adobe
Photoshop CS2.
Western blotting
Western blots were performed to assess total levels of
Npr protein in cell lysates generated by digestion of dis-
eased (grade III to IV) and non-diseased (grade 0 to I)
cartilage from suitable donors. Human chondrocytes
(1 × 106) were lysed in 1% SDS and 40 μg of total pro-
tein determined by bicinchoninic acid (BCA) assay was
loaded onto SDS-PAGE gels for electrophoresis
(Thermo Scientific, Rockford, IL, USA). After semi-dry
transfer to nitrocellulose membranes, Nprs were
detected by incubation overnight with primary antibo-
dies (1:500) for Npr2 (ab14357, Abcam) or Npr3
(ab97389, Abcam) and detected by IrDye-labelled anti-
bodies for visualisation on the Odyssey system (Li-Cor
Biosciences, Lincoln, NE, USA). GAPDH (1:2000) served
as an internal control (OAEA00006, Cambridge Bios-
ciences, UK).
Statistics
For free-swelling studies, data represent the mean and
standard error of the mean (SEM) values of up to 25
replicates containing chondrocytes isolated from four to
five donors. For the mechanical loading experiments,
biochemical and gene-expression data represent the
mean and SEM values of up to 13 replicates from three
to four separate experiments/donors. Statistical analysis
was performed with two-way analysis of variance
(ANOVA) and the multiple post hoc Bonferroni-
corrected t-tests to compare differences between the
various treatment groups, as indicated in the figure
legend. For gene-expression data, ratio values were log
transformed before analysis by two-way ANOVA and
post hoc Bonferroni-corrected t-test. In all cases, a level
of 5% was considered statistically significant (P < 0.05).
Results
Natriuretic peptide receptor expression increased with
age and disease severity
Immunofluorescence microscopy showed weak localised
staining for Npr2 expression in non-diseased cartilage
from donors aged between 55 and 60 years (Figure 1A
and 1B). In contrast, there was a greater abundance of
Npr2 expression in diseased cartilage and the number of
positive cells significantly increased with age (P < 0.05)
(Figure 1B), showing distinct cell membrane localisation
(Figure 1B) and expression by western blot analysis
(inset, Figure 1B). In non-diseased cartilage, similar
levels of Npr3 expression were found for both age
groups, with some labelling in the cytoplasm of these
cells (Figure 1A). However, Npr3 expression was
observed not to be expressed by all cells in older carti-
lage (Figure 1B). In diseased tissue, the number of
Npr3-positive cells significantly increased with age (P <
0.01) (Figure 1C), such that greater levels of Npr3 stain-
ing was observed in the cell membrane (Figure 1C).
Analysis by western blotting showed expression of Npr3
in non-diseased and diseased tissue (inset, Figure 1C). A
distinct pattern was therefore observed, with an age-
related increase in expression of both Npr2 and Npr3 in
diseased cartilage compared to non-diseased tissue.
Natriuretic peptide receptors mediate a reduction in
catabolic effects via cGMP
Treatment of chondrocyte/agarose constructs with IL-1b
led to an increase in catabolic effects involving enhanced
NO production and PGE2 release, and a reduction in
GAG synthesis (all P < 0.001) (Figure 2A-C). However,
co-treatment with CNP prevented IL-1b-induced cata-
bolic effects, resulting in a reduction of NO (P < 0.01)
(Figure 2A) and PGE2 release (P < 0.05) (Figure 2B) and
restoration of GAG synthesis similar to untreated con-
trol values (P < 0.01) (Figure 2C). To assess the differen-
tial effects of Npr2 or Npr3 signalling, specific peptides
that influence the natriuretic peptide receptors were
incubated for 48 hours with CNP in IL-1b-treated con-
structs. Inhibition of the Npr2 receptor with P19
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Figure 1 Comparison of natriuretic peptide receptor 2 (Npr2) and Npr3 expression in non-diseased (grade 0/I) and diseased (grade III
to IV) cartilage. Tissues were taken from donors aged 55 to 60 and 80 to 85 years. Paraffin-embedded sections from a single donor aged 60
years were stained with Npr2 or Npr3 antibodies (green) and examined by immunofluoresence microscopy (A). Nuclei (blue) were stained with
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maintained catabolic activities resulting in higher levels
of NO and PGE2 production when compared to con-
structs co-cultured with CNP and IL-1b (P < 0.001 and
P < 0.01) (Figure 2A and 2B, respectively). In contrast,
treatment with the Npr3 agonist, cANF4-23 had the
opposite effect and reduced NO and PGE2 release in
constructs co-cultured with CNP and IL-1b (P < 0.001
and P < 0.01) (Figure 2A and 2B, respectively). These
findings suggest that the reduction in catabolic activities
in response to IL-1b are mediated by both natriuretic
peptide receptors.
We next examined the effect of inhibiting sGC with
ODQ, as the NO and CNP pathways intersect in the
intracellular signalling cascade and are both inducers of
cGMP. The effect of ODQ was identical to P19, result-
ing in high levels of NO and PGE2 release (P < 0.001
and P < 0.05) (Figure 2A and 2B, respectively) without
significantly affecting GAG synthesis in constructs co-
cultured with CNP and IL-1b. The cytokine did not sig-
nificantly influence cGMP levels in chondrocyte/agarose
constructs (Figure 2D). However, CNP significantly
increased cGMP levels in the absence of IL-1b resulting
in enhanced GAG synthesis when compared to
untreated controls (all P < 0.001). Co-stimulation with
IL-1b, CNP and the soluble guanylyl cyclase (sGC) inhi-
bitor significantly reduced total cGMP levels when com-
pared to constructs treated with CNP and IL-1b (P <
0.05). However, no further significant change was
observed with cANF4-23 or P19 on cGMP levels in con-
structs co-cultured with CNP and IL-1b, resulting in
minimal corresponding changes in GAG synthesis.
The relationship between cGMP and GAG synthesis is
interesting. The presence of CNP significantly increased
cGMP levels and GAG synthesis. However, the anabolic
response was inhibited with IL-1b and reversed with
CNP in IL-1b-treated constructs. Both the sGC and Npr2
inhibitor but not the Npr3 inhibitor reduced cGMP levels
similar to IL-1b-treated constructs. This reduction in
cGMP levels by blockade of the natriuretic peptide path-
way results in basal levels of GAG synthesis similar to
untreated controls. It is evident that CNP acts as a cGMP
inducer that mediates anabolic effects via Nprs in
chondrocytes.
Dynamic compression and natriuretic peptide receptors
counteracts the pathways induced by IL-1b
The effect of CNP and dynamic compression on catabolic
(NO and PGE2) and anabolic (GAG synthesis, cGMP)
activities using peptides, which modulate the Npr2 (P19)
and Npr3 pathway (cANF4-23), are shown in Figure 3. In
the absence and presence of IL-1b, dynamic compression
significantly inhibits NO production in chondrocyte/agar-
ose constructs (both P < 0.001; Figure 3A). In unstrained
constructs, CNP inhibits NO production (P < 0.05), but
there was no further significant effect with dynamic com-
pression. In the presence of IL-1b, stimulation with CNP
and dynamic compression reduced NO release (P < 0.05)
and the inhibitory effect was not influenced further with
cANF4-23 or P19. This resulted in broadly similar percen-
tage change values which ranged between 21 and 39%.
In the absence and presence of CNP, dynamic com-
pression did not significantly influence PGE2 release
(Figure 3B). In unstrained constructs, IL-1b enhanced
PGE2 production and this effect was reduced by
dynamic compression (both P < 0.001) or by stimulation
with CNP (P < 0.01). Co-stimulation with dynamic com-
pression and the Npr3 agonist reduced PGE2 release
with a percentage change value broadly similar for con-
structs cultured with IL-1b and/or CNP. In contrast, the
Npr2 inhibitor reduced compression-induced inhibition
of PGE2 release, implying that this receptor is important
in preventing catabolic effects.
Dynamic compression increased GAG synthesis in the
presence and absence of CNP (both P < 0.001; Figure 3C).
The compression-induced stimulatory effect was reduced
with IL-1b and restored with CNP in cytokine-treated
unstrained (P < 0.001) or strained constructs (P < 0.01).
The presence of cANF4-23 increased compression-induced
stimulation of GAG synthesis (P < 0.001) with percentage
change values greater for CNP-treated constructs when
compared to untreated controls (123 and 69%, respec-
tively). However, P19 abolished compression-induced
synthesis of GAG in IL-1b-treated constructs, suggesting
that the Npr2 receptor is important in mediating anabolic
effects in the presence of the cytokine (Figure 3C).
Furthermore, we examined the effect of CNP on cGMP
levels (Figure 3D). Dynamic compression significantly
increased total cGMP content (P < 0.05). In unstrained
constructs, the presence of CNP and/or IL-1b increased
cGMP levels (both P < 0.01) and the response was reduced
with dynamic compression (P < 0.05). The presence of
cANF but not P19 enhanced cGMP levels and the
response was not influenced further with dynamic
compression.
Dynamic compression increased CNP levels and
natriuretic peptide receptor expression which mediate an
anabolic response
Since mechanical loading enhanced the pathways induced
by CNP, it was important to examine whether dynamic
compression could influence gene expression of Nprs and
CNP levels (Figure 4). In the presence and absence of
CNP, dynamic compression significantly increased Npr2
gene expression (both P < 0.01) (Figure 4A). Dynamic
compression increased Npr2 expression in the absence
and presence of CNP (both P < 0.01; Figure 4A, but not
with IL-1b. In untreated constructs, dynamic compression
increased Npr3 expression (P < 0.001) and the response
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was reduced with CNP (P < 0.05) (Figure 4B). In
unstrained constructs, IL-1b significantly increased Npr3
expression (P < 0.01) and this effect was inhibited with
dynamic compression (P < 0.001). Either dynamic com-
pression (P < 0.05) or the presence of IL-1b significantly
increased CNP gene expression (P < 0.01; Figure 4C). The
stimulatory effect was not influenced further with CNP
and/or IL-1b and/or stimulation with dynamic compres-
sion. In addition, CNP concentration was significantly
enhanced with dynamic compression (P < 0.001) and/or
IL-1b (P < 0.05) (Figure 4D). This led to the induction of
aggrecan and collagen type II gene expression by dynamic
compression in constructs cultured with CNP or cANF
but not with P19 (Figure 4E, F).
We next examined whether mechanical loading could
influence endogenous CNP signalling. P19 and cANF4-23
did not influence the inhibitory effect of NO release in
response to dynamic compression (Figure 5A). However,
in the presence of IL-1b, the inhibitory response was
abolished with P19 but not with cANF. In addition,
compression did not influence PGE2 release in the
absence of P19 but the levels were increased with P19
or reduced with cANF4-23 (both P < 0.01) (Figure 5B).
IL-1b enhanced PGE2 release and stimulation with
dynamic compression reduced PGE2 release with cANF
(P < 0.01) but not with P19. In unstrained constructs,
GAG synthesis was enhanced with cANF4-23 (both P <
0.001) (Figure 5C). However, the compression-induced
stimulatory effect on GAG synthesis was abolished with
P19 and significantly enhanced with cANF4-22 in the
absence (P < 0.001) and presence of IL-1b (P < 0.01).
The data demonstrate that mechanical loading-induced
CNP is protective and stimulates an anabolic response
by altering the expression of the Nprs and CNP levels.
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Figure 3 Effect of dynamic compression and pharmacological agents that influence the natriuretic peptide receptor 2 (Npr2) or Npr3
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Discussion
The signalling pathways leading to the cytoprotective
effects of CNP are currently unclear. In this study, we
examined the mechanisms by which CNP leads to a
reduction of catabolic activities induced by IL-1b. CNP
predominantly activates Npr2, which underlies guanylyl
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cyclase activity and mediates several cellsignalling effects
through the synthesis of cGMP. In addition, CNP binds
to Npr3, which does not possess guanylate cyclase func-
tionality and until recently, was thought to be devoid of
any natriuretic peptide signalling capacity. Although sev-
eral studies have suggested a role for Npr2 signalling in
cartilage and bone, recent evidence demonstrates that
the Gi/o binding domain in Npr3 activates ERK 1/2,
which is important in endothelial and vascular smooth
muscle cell proliferation and cardiovascular homeostasis
[4,8,14]. Both Npr2 and Npr3 play a role in cartilage
and bone homeostasis in knockout mouse models,
although the precise mechanisms remain unclear [5,7].
Furthermore, in rat osteoblasts, expression of Nprs was
shown to change with age with a shift in expression
from Npr2 to Npr3 in older rats [13].
Given the role of age in the pathogenesis of OA, we
were interested to observe any disease and/or age-
related effects of Nprs and compare expression at the
mRNA and protein levels in non-diseased and OA-
affected cartilage isolated from donors undergoing total
knee arthroplasty with an age range of 55 to 85 years.
The present study confirmed dominant expression of
Nprs in diseased cartilage, when compared to non-dis-
eased tissue from the same donor. In addition, there
was significant upregulation of both receptors in older
cartilage (age 70 years), such that Npr3 expression
appeared to be greater in abundance than Npr2 in tissue
taken from the same donor. However, we did not com-
pare Npr expression in young cartilage (age range from
30 to 39 or 40 to 49 years) isolated from a healthy joint
and this merits further investigation. In addition, Npr3 but
not Npr2 mRNA levels were significantly higher with IL-
1b when compared to untreated controls. Given the chon-
droprotective nature of CNP, the present study suggests
that OA chondrocytes upregulate natriuretic peptide sig-
nalling as a consequence of the pro-inflammatory process,
possibly as a means to restrict disease progression.
Furthermore, Nprs appear to be linked with the age and/
or the disease process enabling osteoarthritic tissue to
retain its ability to respond to CNP if administered as a
therapeutic intervention. Indeed, the next step in this
research is to test this hypothesis in an in vivo mouse
model, which represents early-stage OA, enabling exploi-
tation of transgenic animals with deficiencies in CNP sig-
nalling (for example, tissue-specific Npr2-/-, Npr3-/-) in the
absence and presence of agents that stimulate the Npr
pathways. For example, mice lacking Npr3 facilitate sub-
type switching during differentiation from proliferating to
hypertrophic chondrocytes in the growth plate of the fetal
mouse tibia [24]. However, no studies have examined
whether mice lacking Npr3 stimulate pro-inflammatory
cytokines leading to both a loss of cGMP signalling and
the chondroprotective effects in cartilage. Thus, the
actions of pro-inflammatory cytokines on natriuretic pep-
tide signalling in chondrocyte functions warrant further
examination.
We investigated whether Npr pathways have differen-
tial or overlapping protective roles in maintaining carti-
lage homeostasis. This was achieved by utilising two
pharmacological agents that specifically inhibit Npr2
(P19) or activate Npr3 (cANF4-23). In the present study,
the Npr2 antagonist prevented the protective effects of
CNP on catabolic activities by maintaining high levels of
NO and PGE2 release in IL-1b-treated constructs, whilst
not affecting GAG synthesis. The findings are in agree-
ment with a recent study, which reported that CNP
could signal through Npr3 and exert an anabolic
response in endothelial cells [14]. As shown in the sche-
matic in Figure 6, Npr3 mediates several anabolic effects
linked to cartilage homeostasis involving adenylate
cyclase inhibition and stimulation of the G1 protein,
phospholipase C (PLC) and inosital triphosphate (IP3)
pathway [13,25]. In chondrocytes, PLC activation and IP3
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Figure 5 Effect of dynamic compression and pharmacological agents that influence the natriuretic peptide receptor 2 (Npr2) or Npr3
pathways. Absolute values for nitric oxide (NO) release (A), prostaglandin E2 (PGE2) production (B) and glycosaminoglycan (GAG) synthesis (C).
Constructs were cultured in the presence and absence of 0.5 μM P19 or 1 μM cANF4-23 for 48 hours. Error bars represent the mean and standard
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presented as a percentage change of the unstrained controls, with SEM values are shown in brackets. Asterisks indicate significant comparisons
in unstrained (black bars) and strained (white bars) constructs for the multiple treatment conditions. All other comparisons (not indicated) were
not significant.
Peake et al. Arthritis Research & Therapy 2013, 15:R76
http://arthritis-research.com/content/15/4/R76
Page 10 of 14
generation contribute to Ca2+ release from intracellular
stores, which is known to support cartilage homeostasis
by mediating the anabolic effects involved in mechano-
transduction [26-30]. These findings suggest that Npr3
could influence adenylate cyclase/cAMP signalling,
thereby altering the relative balance between the cyclic
nucleotides and downstream signal transduction events
(Figure 6).
There was strong parallelism in the actions of CNP on
cGMP induction, resulting in enhanced GAG synthesis
and reduction of catabolic effects induced by IL-1b. Both
NO and CNP signalling lead to the synthesis of cGMP,
indicating there is cross-talk between IL-1b/NO/sGC/
cGMP-mediated catabolism and CNP-mediated chon-
droprotection [31]. It has previously been reported that
the temporal differences in NO/cGMP signalling leads to
differential, biphasic effects [32]. Indeed, in a previous
study, catabolic events involving NO release are
characterized by an initial spike in cGMP levels, in con-
trast to anabolic signals, which are linked to low, more
sustained cGMP turnover [32]. A similar mechanism
may explain the parallel involvement of cGMP in our
model, whereby the IL-1b-induced NO/sGC/cGMP sig-
nalling route mediates catabolic activities in contrast to
the Npr2/GC-B/cGMP/PKGII pathway, which is ana-
bolic. Interestingly, in our experiments we showed the
presence of extracellular cGMP, exceeding intracellular
concentrations, which were both reduced with the sGC
inhibitor, ODQ. These results are consistent with studies
in smooth muscle cells or brain astrocytes, which demon-
strates a similar pattern of extracellular cGMP levels
when compared to intracellular concentrations reported
to be less than 20 pM [33,34]. Recent studies suggest that
members of the ATP-binding cassette transport system,
in particular multidrug resistance protein 5 (MRP5), reg-
ulate extrusion of cGMP and prevent hyaluronan export
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in fibroblasts [35,36]. The biological significance of
cGMP transporters in chondrocytes have yet to be clari-
fied. In contrast, there is ample evidence that shows the
clinical importance of hyaluronan in OA treatment [37].
A recent study analysed the effects of enhanced cGMP
levels with PDE5 inhibitors demonstrating prevention of
HA over-production and proteoglycan/collagen loss in
IL-1a-treated cartilage explants [38]. However, regulation
of HA export through MRP5 and CNP-linked Npr2/
cGMP signalling has not been previously described in
human cartilage and merits further examination.
To test the hypothesis that mechanical loading interferes
with the signals induced by natriuretic peptides, we incu-
bated constructs with agonists or antagonists of the Npr2
and Npr3 pathways to show that biomechanical and
natriuretic peptide signals stabilise cartilage homeostasis.
In the presence of CNP, specific inhibition of Npr2 abol-
ished the anabolic response to mechanical loading and
prevented loading-induced inhibition of NO and PGE2
release. In contrast, the presence of the Npr3 agonist had
the opposite effect and significantly increased GAG synth-
esis and cGMP levels in response to mechanical loading
and reduced NO and PGE2 release comparable to control
samples. cGMP levels are a good index of CNP/Npr2 sig-
nalling, particularly since the increase in cGMP in
response to CNP is blocked with P19. The Nprs are there-
fore critical mediators necessary for anabolic signalling in
response to CNP and mechanical loading. In a previous
study, we described PKGII as the principal mediator of
cGMP signals, thereby implying that the Npr2/sGC/
cGMP/PKGII pathway has a positive role in cartilage
homeostasis [3]. Indeed, mechanical strain was reported to
significantly increase cGMP synthesis in mouse podocytes
and induce subsequent anabolic activities [39]. This is in
agreement with the present study, which showed that sig-
nals involving compression or CNP are cGMP inducers
leading to anabolic events.
Furthermore, the present data demonstrate differential
effects of Nprs on NO and PGE2 release, implicating
cross-talk with other pathways involving IL-1b. For
example, mechanical loading is known to influence sev-
eral overlapping genes that influence the NFB and mito-
gen-activated protein kinase (MAPK) pathways leading to
downregulation of NO and PGE2 production [39-43].
However, the time course of phosphorylation events in
response to CNP, IL-1b and dynamic compression have
not been presented in the current study. A limitation of
the ex vivo 3D/bioreactor model, are the difficulties asso-
ciated with isolating cell lysates from pooled constructs,
which are largely agarose gel and associated media-serum
contaminant rather than being cell derived. Compression,
IL-1b or CNP could affect ERK phosphorylation, but may
also have action on other MAPK signalling pathways,
which alter their activation state in a time-dependent
manner. Indeed, the presence of the critical mechano-
senstive integrins and cytoskeleton will additionally
counteract IL-1b-induced catabolic activities [43-45].
Indeed, biomechanical signals have been shown to upre-
gulate both cGMP and cAMP production in osteoblasts
or PLC signalling in chondrocytes, which are critical fac-
tors involved in the Npr2 and Npr3 pathways [29,46-48].
We therefore asked the question whether mechanical
loading could directly influence expression of Nprs, pro-
viding an autocrine/paracrine mechanism for the differ-
ential effects of CNP (Figure 6). Indeed, the present study
confirmed CNP levels and Npr expression were increased
with mechanical loading in chondrocyte/agarose con-
structs, demonstrating an endogenous role of these fac-
tors. Our observations are in agreement with a previous
study, which demonstrates the induction of CNP in
response to shear stress in vascular cells [49]. Further-
more, the presence of IL-1b or TNFa significantly
induced CNP expression in endothelial cells, supporting
an endogenous role for natriuretic peptide signalling in
the prevention of pro-inflammatory induced signals [50].
In summary, Nprs are influenced by CNP, IL-1b, age,
disease severity and mechanical loading. The differential
effects of CNP are dependent on the combination of
factors that influence cartilage homeostasis, leading to
the activation of multiple, temporal events, which affect
downstream pathways. Biomechanical signals stimulate
natriuretic peptide signalling, which is protective and
maintains cartilage health. Future studies are needed to
confirm the beneficial effects of CNP and mechanical
signals in an in vivo mouse model that represents early
stage OA.
Conclusions
CNP plays a critical role in the development and regula-
tion of articular cartilage by promoting extracellular
matrix production and chondrocyte proliferation. Our
previous studies demonstrate that CNP acts to inhibit
catabolic signals in response to IL-1b, and that these
effects are synergistic with the protective stimuli
induced by mechanical loading. The present study
demonstrates that endogenous CNP/Npr2/cGMP signal-
ling route mediates anabolic events and prevents cata-
bolic activities induced by IL-1b. Stimulation with
biomechanical signals and natriuretic peptide signals
further augments the anabolic response, resulting in a
reduction of catabolic events mediated by the Npr2/GC/
cGMP route. Therapeutic application of CNP, or inter-
ventions targeted to Nprs to mimic the actions of CNP
should, therefore, be considered to speed up repair
mechanisms and stabilise cartilage homeostasis in
osteoarthritic conditions.
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